FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL							
OMB Number: 3235-02							
Estimated average burden							
hours per response	0.5						

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the

Investment Company Act of 1940

(Print or Ty	pe Responses)																	
Name and Address of Reporting Person * MCGRATH JOHN					2. Issuer Name and Ticker or Trading Symbol Atara Biotherapeutics, Inc. [ATRA]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner					
(Last) (First) (Middle) 611 GATEWAY BOULEVARD, SUITE 900 (Street) SOUTH SAN FRANCISCO, CA 94080 (City) (State) (Zip)				3. Date of Earliest Transaction (Month/Day/Year) 01/11/2018									Director						
				4. If A	4. If Amendment, Date Original Filed(Month/Day/Year)									6. Individual or Joint/Group Filing(Check Applicable Line) X_ Form filed by One Reporting Person Form filed by More than One Reporting Person					
				Table I - Non-Derivative Securities Acqui								Acquired.							
(Instr. 3) Date		2. Transaction Date (Month/Day/Year	2A. Deemed Execution Date, if		3. Transa Code (Instr. 8)	action	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			red 5. A (D) Own	5. Amount of Securities Beneficially				7. Nature of Indirect Beneficial Ownership (Instr. 4)				
							Code	v	Amoui	(A) c		Price				or Indirect (I) (Instr. 4)	(111541. 1)		
Common	Stock		01/11/2018				S(1)	V	3,500		\$	93,	154			D			
Common	Stock		01/12/2018				M ⁽¹⁾		30,00	0 A	\$ 1		,154]	D			
Common	Stock		01/12/2018				S ⁽¹⁾		3,500	D	\$ 22 (3)		,654]	D			
Common Stock 01/12/2018					S(1)		30,00	0 D	\$ 2 (4)	189	89,654		1	D					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year	3A. Deemed Execution Date	(e.g., po 4. Tran Cod	uts, on sact	5. Ition of Der Sec (A) Dis (D)	arrants, o Number rivative curities quired o or sposed of	ptions. 6. Date Expira	isposed of, or, convertible e Exercisable ation Date h/Day/Year)		e curit nd		d f		9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	Owners Form of Derivate Security Direct (or Indire	Ownersh (Instr. 4) D) ect		
				Со	Code V		(D)	Date Exerci	Esable D	xpiratio ate	n	Title	Amount or Number of Shares						
Employee Stock Option (Right to Buy)	\$ 11	01/12/2018		M			30,000	<u>(</u> 5	5) 1	0/14/20	021	Common Stock		\$ 0	10,000	D			
Repor	ting O	wners																	
Reporting Owner Name / Address					Relationships														
MCGRATH JOHN 611 GATEWAY BOULEVARD SUITE 900				0% Own	% Owner Officer Other EVP & Chief Financial Officer														

Signatures

/s/ Kim Merritt, Attorney-in-Fact for John F. McGrath, Jr.	01/12/2018		
**Signature of Reporting Person	Date		

Explanation of Responses:

SOUTH SAN FRANCISCO, CA 94080

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Transaction pursuant to Rule 10b5-1 Plan adopted July 6, 2016.
- (2) The price in Column 4 is a weighted average sale price. The prices actually received ranged from \$20.70 to \$20.925. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- (3) The price in Column 4 is a weighted average sale price. The prices actually received ranged from \$22.15 to \$22.35. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- (4) The price in Column 4 is a weighted average sale price. The prices actually received ranged from \$25.00 to \$25.025. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- (5) 1/48th of the shares subject to the stock option vest and become exercisable each month following October 15, 2014.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.